| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8906890 | BAYER HLTHCARE | Very low-dosed solid oral dosage forms for HRT |
Oct, 2031
(8 years from now) | |
Angeliq is owned by Bayer Hlthcare.
Angeliq contains Drospirenone; Estradiol.
Angeliq has a total of 1 drug patent out of which 0 drug patents have expired.
Angeliq was authorised for market use on 28 September, 2005.
Angeliq is available in tablet;oral dosage forms.
The generics of Angeliq are possible to be released after 22 October, 2031.
Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient
Market Authorisation Date: 28 September, 2005
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage
ANGELIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic